Compare QTTB & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QTTB | BTAI |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.3M | 35.6M |
| IPO Year | 2018 | 2018 |
| Metric | QTTB | BTAI |
|---|---|---|
| Price | $6.37 | $1.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $13.00 | ★ $23.00 |
| AVG Volume (30 Days) | 349.4K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.78 | 75.63 |
| EPS | ★ 2.42 | N/A |
| Revenue | ★ $53,737,000.00 | N/A |
| Revenue This Year | N/A | $141.28 |
| Revenue Next Year | N/A | $1,921.56 |
| P/E Ratio | $2.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.38 | $1.08 |
| 52 Week High | $8.05 | $8.08 |
| Indicator | QTTB | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 54.11 | 33.87 |
| Support Level | $3.49 | N/A |
| Resistance Level | $7.80 | $1.77 |
| Average True Range (ATR) | 0.93 | 0.12 |
| MACD | -0.13 | -0.03 |
| Stochastic Oscillator | 34.32 | 14.93 |
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.